BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk A/S (NVO) Announces Additional Donation to National Hemophilia Foundation's "Campaign for Our Future"


4/16/2010 11:40:58 AM

PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- In observance of World Hemophilia Day on April 17, Novo Nordisk announced it has further contributed $600,000 to the National Hemophilia Foundation's (NHF) "Campaign for Our Future." The goal of this five-year, multi-million dollar capital campaign is to provide support for people with bleeding disorders by building national capacity through the NHF's chapter network, maintaining access to care where it exists and creating new opportunities where access is lacking. This contribution is in addition to Novo Nordisk's initial donation of $2 million in 2008 that launched the campaign nationwide.

With this additional funding from Novo Nordisk, the NHF will be able to advance an aggressive research agenda. This new research agenda includes cultivating the interest of professionals to join and stay in the field of hemophilia; building coalitions with other disease groups, government agencies, and biotechnology companies; and engaging top scientists to be part of a strategic alliance to discuss, recommend and implement future research initiatives.

Hemophilia is a chronic, inherited bleeding disorder that occurs because certain blood clotting factors are missing or do not work properly. People with hemophilia are missing one of the body's natural clotting factors, so they may need special treatment to make their blood clot.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.

Photo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comNovo Nordisk





Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES